Specifically, this could involve evaluating SOCS2 expression levels in RA patient samples and employing CRISPR-based techniques to manipulate SOCS2 expression in RA cellular models, thereby clarifying its impact on inflammatory responses and joint damage. The gene discussed is SOCS2; the disease is rheumatoid arthritis.